Literature DB >> 25392212

Less is more: Ebola virus surface glycoprotein expression levels regulate virus production and infectivity.

Gopi S Mohan1, Ling Ye1, Wenfang Li1, Ana Monteiro2, Xiaoqian Lin1, Bishu Sapkota3, Brian P Pollack4, Richard W Compans5, Chinglai Yang5.   

Abstract

UNLABELLED: The Ebola virus (EBOV) surface glycoprotein (GP1,2) mediates host cell attachment and fusion and is the primary target for host neutralizing antibodies. Expression of GP1,2 at high levels disrupts normal cell physiology, and EBOV uses an RNA-editing mechanism to regulate expression of the GP gene. In this study, we demonstrate that high levels of GP1,2 expression impair production and release of EBOV virus-like particles (VLPs) as well as infectivity of GP1,2-pseudotyped viruses. We further show that this effect is mediated through two mechanisms. First, high levels of GP1,2 expression reduce synthesis of other proteins needed for virus assembly. Second, viruses containing high levels of GP1,2 are intrinsically less infectious, possibly due to impaired receptor binding or endosomal processing. Importantly, proteolysis can rescue the infectivity of high-GP1,2-containing viruses. Taken together, our findings indicate that GP1,2 expression levels have a profound effect on factors that contribute to virus fitness and that RNA editing may be an important mechanism employed by EBOV to regulate GP1,2 expression in order to optimize virus production and infectivity. IMPORTANCE: The Ebola virus (EBOV), as well as other members of the Filoviridae family, causes severe hemorrhagic fever that is highly lethal, with up to 90% mortality. The EBOV surface glycoprotein (GP1,2) plays important roles in virus infection and pathogenesis, and its expression is tightly regulated by an RNA-editing mechanism during virus replication. Our study demonstrates that the level of GP1,2 expression profoundly affects virus particle production and release and uncovers a new mechanism by which Ebola virus infectivity is regulated by the level of GP1,2 expression. These findings extend our understanding of EBOV infection and replication in adaptation of host environments, which will aid the development of countermeasures against EBOV infection.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25392212      PMCID: PMC4300637          DOI: 10.1128/JVI.01810-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  59 in total

Review 1.  Evolutionary conservation of the membrane fusion machine.

Authors:  P Poumbourios; R J Center; K A Wilson; B E Kemp; B Kobe
Journal:  IUBMB Life       Date:  1999-08       Impact factor: 3.885

2.  Ebola virus secretory glycoprotein (sGP) diminishes Fc gamma RIIIB-to-CR3 proximity on neutrophils.

Authors:  A L Kindzelskii; Z Yang; G J Nabel; R F Todd; H R Petty
Journal:  J Immunol       Date:  2000-01-15       Impact factor: 5.422

3.  Downregulation of beta1 integrins by Ebola virus glycoprotein: implication for virus entry.

Authors:  A Takada; S Watanabe; H Ito; K Okazaki; H Kida; Y Kawaoka
Journal:  Virology       Date:  2000-12-05       Impact factor: 3.616

4.  Efficient cell infection by Moloney murine leukemia virus-derived particles requires minimal amounts of envelope glycoprotein.

Authors:  E Bachrach; M Marin; M Pelegrin; G Karavanas; M Piechaczyk
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

5.  Moving the glycoprotein gene of vesicular stomatitis virus to promoter-proximal positions accelerates and enhances the protective immune response.

Authors:  E B Flanagan; L A Ball; G W Wertz
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

6.  Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury.

Authors:  Z Y Yang; H J Duckers; N J Sullivan; A Sanchez; E G Nabel; G J Nabel
Journal:  Nat Med       Date:  2000-08       Impact factor: 53.440

7.  A PPxY motif within the VP40 protein of Ebola virus interacts physically and functionally with a ubiquitin ligase: implications for filovirus budding.

Authors:  R N Harty; M E Brown; G Wang; J Huibregtse; F P Hayes
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

Review 8.  Ebola haemorrhagic fever.

Authors:  Heinz Feldmann; Thomas W Geisbert
Journal:  Lancet       Date:  2011-03-05       Impact factor: 79.321

9.  Antigenic subversion: a novel mechanism of host immune evasion by Ebola virus.

Authors:  Gopi S Mohan; Wenfang Li; Ling Ye; Richard W Compans; Chinglai Yang
Journal:  PLoS Pathog       Date:  2012-12-13       Impact factor: 6.823

10.  Ebola virus entry requires the cholesterol transporter Niemann-Pick C1.

Authors:  Jan E Carette; Matthijs Raaben; Anthony C Wong; Andrew S Herbert; Gregor Obernosterer; Nirupama Mulherkar; Ana I Kuehne; Philip J Kranzusch; April M Griffin; Gordon Ruthel; Paola Dal Cin; John M Dye; Sean P Whelan; Kartik Chandran; Thijn R Brummelkamp
Journal:  Nature       Date:  2011-08-24       Impact factor: 49.962

View more
  24 in total

1.  Mechanistic understanding of N-glycosylation in Ebola virus glycoprotein maturation and function.

Authors:  Bin Wang; Yujie Wang; Dylan A Frabutt; Xihe Zhang; Xiaoyu Yao; Dan Hu; Zhuo Zhang; Chaonan Liu; Shimin Zheng; Shi-Hua Xiang; Yong-Hui Zheng
Journal:  J Biol Chem       Date:  2017-02-14       Impact factor: 5.157

2.  A Recombinant Rabies Virus Expressing the Marburg Virus Glycoprotein Is Dependent upon Antibody-Mediated Cellular Cytotoxicity for Protection against Marburg Virus Disease in a Murine Model.

Authors:  Rohan Keshwara; Katie R Hagen; Tiago Abreu-Mota; Amy B Papaneri; David Liu; Christoph Wirblich; Reed F Johnson; Matthias J Schnell
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

Review 3.  T Lymphocytes as Measurable Targets of Protection and Vaccination Against Viral Disorders.

Authors:  Anne Monette; Andrew J Mouland
Journal:  Int Rev Cell Mol Biol       Date:  2018-10-24       Impact factor: 6.813

4.  A Replicating Single-Cycle Adenovirus Vaccine Against Ebola Virus.

Authors:  Stephanie S Anguiano-Zarate; William E Matchett; Pramod N Nehete; Jagannadha K Sastry; Andrea Marzi; Michael A Barry
Journal:  J Infect Dis       Date:  2018-11-05       Impact factor: 5.226

Review 5.  Therapeutic vaccination strategies against EBOV by rVSV-EBOV-GP: the role of innate immunity.

Authors:  Amanda N Pinski; Ilhem Messaoudi
Journal:  Curr Opin Virol       Date:  2021-11-05       Impact factor: 7.090

Review 6.  Addressing Therapeutic Options for Ebola Virus Infection in Current and Future Outbreaks.

Authors:  Azizul Haque; Didier Hober; Joel Blondiaux
Journal:  Antimicrob Agents Chemother       Date:  2015-07-27       Impact factor: 5.191

7.  Intradermal Vaccination With Adjuvanted Ebola Virus Soluble Glycoprotein Subunit Vaccine by Microneedle Patches Protects Mice Against Lethal Ebola Virus Challenge.

Authors:  Ying Liu; Ling Ye; Fang Lin; Yasmine Gomaa; David Flyer; Ricardo Carrion; Jean L Patterson; Mark R Prausnitz; Gale Smith; Gregory Glenn; Hua Wu; Richard W Compans; Chinglai Yang
Journal:  J Infect Dis       Date:  2018-11-22       Impact factor: 5.226

8.  Soluble Glycoprotein Is Not Required for Ebola Virus Virulence in Guinea Pigs.

Authors:  Thomas Hoenen; Andrea Marzi; Dana P Scott; Friederike Feldmann; Julie Callison; David Safronetz; Hideki Ebihara; Heinz Feldmann
Journal:  J Infect Dis       Date:  2015-05-09       Impact factor: 5.226

Review 9.  Molecular mechanisms of Ebola virus pathogenesis: focus on cell death.

Authors:  L Falasca; C Agrati; N Petrosillo; A Di Caro; M R Capobianchi; G Ippolito; M Piacentini
Journal:  Cell Death Differ       Date:  2015-05-29       Impact factor: 15.828

10.  Novel functional hepatitis C virus glycoprotein isolates identified using an optimized viral pseudotype entry assay.

Authors:  Richard A Urbanowicz; C Patrick McClure; Barnabas King; Christopher P Mason; Jonathan K Ball; Alexander W Tarr
Journal:  J Gen Virol       Date:  2016-07-06       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.